This clinical trial, sponsored by Imam Abdulrahman Bin Faisal University, explores the efficacy of BEMER therapy on erectile dysfunction (ED) in male patients with relapsing-remitting multiple sclerosis (RRMS). Given the significant prevalence of ED in MS patients and the limited treatment options available, a successful outcome could position BEMER therapy as a novel intervention in a niche market. The trial's findings may attract interest from pharmaceutical companies and medical device manufacturers looking to expand their portfolios in sexual health and neurology. However, the lack of FDA regulation for the device may limit its marketability in certain regions. Competitive analysis should consider existing ED treatments and emerging therapies targeting similar patient demographics.